This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/drugbank/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/national-drug-code-directory/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/uniprotkb/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/genbank/
n6http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n21http://www.rxlist.com/cgi/generic2/
n14http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00040/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00040
rdf:type
n6:Drug
n6:description
29 residue peptide hormone. Glucagon is synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons
n6:dosage
n23:271B4141-363D-11E5-9242-09173F13E4C5 n23:271B4142-363D-11E5-9242-09173F13E4C5
n6:generalReferences
# White CM: A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999 May;39(5):442-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10234590
n6:group
approved
n6:indication
For treatment of severe hypoglycemia, also used in gastrointestinal imaging
n6:manufacturer
n8:271B4139-363D-11E5-9242-09173F13E4C5 n8:271B4138-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00040 n16:DB00040
dcterms:title
Glucagon recombinant
adms:identifier
n4:Q8MJ25 n5:C01501 n7:D00116 n17:PA164779052 n18:Glucagon_recombinant n24:AF529185 n25:DB00040 n26:0002-8031-01
n6:mechanismOfAction
Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion
n6:packager
n8:271B4137-363D-11E5-9242-09173F13E4C5 n8:271B4135-363D-11E5-9242-09173F13E4C5 n8:271B4136-363D-11E5-9242-09173F13E4C5 n8:271B4134-363D-11E5-9242-09173F13E4C5
n6:synonym
His-ser-glu(NH2)-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-glu(NH2)-asp-phe-val-glu(NH2)-trp-leu-met-asp(NH2)-thr Glucagone His-ser-gln-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr Glucagon Glucagonum HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
n6:volumeOfDistribution
* 0.25 L/kg
n19:hasAHFSCode
n22:68-22-12
foaf:page
n10:glucagon.html n21:gluca.htm
n6:Molecular-Formula
n14:271B4146-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n14:271B4145-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:H04AA01
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
9007-92-5
n6:category
n6:clearance
* 13.5  mL/min/kg [Adults with IV 1 mg]
n6:containedIn
n15:271B413B-363D-11E5-9242-09173F13E4C5 n15:271B413C-363D-11E5-9242-09173F13E4C5 n15:271B413A-363D-11E5-9242-09173F13E4C5 n15:271B413F-363D-11E5-9242-09173F13E4C5 n15:271B4140-363D-11E5-9242-09173F13E4C5 n15:271B413D-363D-11E5-9242-09173F13E4C5 n15:271B413E-363D-11E5-9242-09173F13E4C5
n6:Hydrophobicity
n14:271B4143-363D-11E5-9242-09173F13E4C5
n6:Isoelectric-Point
n14:271B4144-363D-11E5-9242-09173F13E4C5